SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer.
Seung Ho BaekJi Hyoung KimSoong June BaeJung Hwan JiYangkyu LeeJoon JeongYoon-Jin ChaSung-Gwe AhnPublished in: Cancers (2022)
Our findings reveal the heterogeneous SP142 PD-L1 expression in TNBC and suggest that PD-L1 evaluation in baseline biopsy might be insufficient to represent the PD-L1 status of whole tumors. In TNBC, vigorous PD-L1 examination using multiple available tumor samples could identify more patients eligible for immune checkpoint blockade.